These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38891113)

  • 1. Tigilanol Tiglate-Induced Changes in Secretome Profiles Alter C-Met Phosphorylation and Cell Surface Protein Expression in H357 Head and Neck Cancer Cells.
    Antwi FD; Awad T; Larin M; Heesom K; Lewis P; Reddell P; Poghosyan Z; Dewitt S; Moseley R; Knäuper V
    Cells; 2024 Jun; 13(11):. PubMed ID: 38891113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate.
    Barnett CME; Broit N; Yap PY; Cullen JK; Parsons PG; Panizza BJ; Boyle GM
    Invest New Drugs; 2019 Feb; 37(1):1-8. PubMed ID: 29667135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes.
    Cullen JK; Boyle GM; Yap PY; Elmlinger S; Simmons JL; Broit N; Johns J; Ferguson B; Maslovskaya LA; Savchenko AI; Mirzayans PM; Porzelle A; Bernhardt PV; Gordon VA; Reddell PW; Pagani A; Appendino G; Parsons PG; Williams CM
    Sci Rep; 2021 Jan; 11(1):207. PubMed ID: 33420238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
    Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
    Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
    Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
    Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor-type Protein tyrosine phosphatase β regulates met phosphorylation and function in head and neck squamous cell carcinoma.
    Xu Y; Zhou J; Carey TE; McHugh JB; Voorhees JJ; Fisher GJ
    Neoplasia; 2012 Nov; 14(11):1015-22. PubMed ID: 23226095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2.
    Hu CT; Cheng CC; Pan SM; Wu JR; Wu WS
    Cell Signal; 2013 Jun; 25(6):1457-67. PubMed ID: 23524339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.
    Yamada S; Imura Y; Nakai T; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
    BMC Cancer; 2017 May; 17(1):334. PubMed ID: 28511645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).
    De Ridder TR; Campbell JE; Burke-Schwarz C; Clegg D; Elliot EL; Geller S; Kozak W; Pittenger ST; Pruitt JB; Riehl J; White J; Wiest ML; Johannes CM; Morton J; Jones PD; Schmidt PF; Gordon V; Reddell P
    J Vet Intern Med; 2021 Jan; 35(1):415-429. PubMed ID: 32542733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.
    Stabile LP; He G; Lui VW; Thomas S; Henry C; Gubish CT; Joyce S; Quesnelle KM; Siegfried JM; Grandis JR
    Clin Cancer Res; 2013 Jan; 19(2):380-92. PubMed ID: 23213056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKT and MET signalling mediates antiapoptotic radioresistance in head neck cancer cell lines.
    Ettl T; Viale-Bouroncle S; Hautmann MG; Gosau M; Kölbl O; Reichert TE; Morsczeck C
    Oral Oncol; 2015 Feb; 51(2):158-63. PubMed ID: 25499462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
    Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
    Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delta-protein kinase C phosphorylation parallels inhibition of nerve growth factor-induced differentiation independent of changes in Trk A and MAP kinase signalling in PC12 cells.
    Wooten MW; Seibenhener ML; Heikkila JE; Mischak H
    Cell Signal; 1998 Apr; 10(4):265-76. PubMed ID: 9617484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC.
    Beizaei K; Gleißner L; Hoffer K; Bußmann L; Vu AT; Steinmeister L; Laban S; Möckelmann N; Münscher A; Petersen C; Rothkamm K; Kriegs M
    Head Neck; 2019 Jan; 41(1):208-215. PubMed ID: 30552828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
    Seiwert TY; Jagadeeswaran R; Faoro L; Janamanchi V; Nallasura V; El Dinali M; Yala S; Kanteti R; Cohen EE; Lingen MW; Martin L; Krishnaswamy S; Klein-Szanto A; Christensen JG; Vokes EE; Salgia R
    Cancer Res; 2009 Apr; 69(7):3021-31. PubMed ID: 19318576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of the HGF/Met signaling in head and neck squamous cell carcinoma: Focus on tumor immunity (Review).
    Liu D; Zhong M; Zhan D; Zhang Y; Liu S
    Oncol Rep; 2020 Dec; 44(6):2337-2344. PubMed ID: 33125120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bi-directional regulation of Ser-985 phosphorylation of c-met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor.
    Hashigasako A; Machide M; Nakamura T; Matsumoto K; Nakamura T
    J Biol Chem; 2004 Jun; 279(25):26445-52. PubMed ID: 15075332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing.
    Xu KP; Yu FS
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2242-8. PubMed ID: 17460286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anomalous inhibition of c-Met by the kinesin inhibitor aurintricarboxylic acid.
    Milanovic M; Radtke S; Peel N; Howell M; Carrière V; Joffre C; Kermorgant S; Parker PJ
    Int J Cancer; 2012 Mar; 130(5):1060-70. PubMed ID: 21400516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46).
    Panizza BJ; de Souza P; Cooper A; Roohullah A; Karapetis CS; Lickliter JD
    EBioMedicine; 2019 Dec; 50():433-441. PubMed ID: 31810818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.